Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Evocutis
Evocutis
Activities:
Regulatory
Research & Development
Skin Care
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Skin Care
Venn Life Sciences acquires trading assets of Evocutis
Including intellectual property rights to Labskin and anti-acne compound SYN1113
Regulatory
Evocutis and Bradford University Collaborate on pigmented LabSkin
Aim to discover improved ways of investigating common pigment-related skin conditions
Regulatory
Evocutis secures first contracts for LabSkin living skin equivalent
Offers an alternative to ethically sensitive and expensive animal and human volunteer testing
Research & Development
Evocutis joins European platform to promote alternatives to animal testing
After making presentation about its LabSkin technology
Ingredients
Syntopix develops microemulsions for healthcare and cosmetic products
Identifies two green surfactants for oral care
Manufacturing
Syntopix plans to buy Leeds Skin
Key attraction of acquisition is Leeds Skin’s LabSkin technology
Ingredients
Syntopix to develop new microemulsions
Wins support from Intelligent Formulation
Subscribe now